Mirum Pharmaceuticals Inc... (MIRM)
NASDAQ: MIRM
· Real-Time Price · USD
50.80
0.10 (0.20%)
At close: Jun 18, 2025, 3:59 PM
51.43
1.24%
After-hours: Jun 18, 2025, 05:52 PM EDT
0.20% (1D)
| Bid | 49.63 |
| Market Cap | 2.52B |
| Revenue (ttm) | 379.25M |
| Net Income (ttm) | -77.34M |
| EPS (ttm) | -1.61 |
| PE Ratio (ttm) | -31.55 |
| Forward PE | -103.45 |
| Analyst | Buy |
| Ask | 54 |
| Volume | 406,651 |
| Avg. Volume (20D) | 432,495 |
| Open | 50.70 |
| Previous Close | 50.70 |
| Day's Range | 49.97 - 51.07 |
| 52-Week Range | 28.56 - 54.23 |
| Beta | 0.95 |
About MIRM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MIRM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MIRM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Mirum Pharmaceuticals Inc. is scheduled to release its earnings on Aug 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+9.75%
Mirum Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
3 months ago
-7.01%
Mirum Pharmaceuticals shares are trading lower after the company reported a Q4 GAPP EPS miss.
1 month ago · businesswire.com
Mirum Pharmaceuticals to Participate in Upcoming Investor ConferencesFOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel the...
1 month ago · https://thefly.com
Mirum Pharmaceuticals price target raised by $4 at Raymond James, here's why29 May
1 month ago · seekingalpha.com
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call TranscriptMirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Andrew McKibben - SVP, Strategic Finance and IR Chris Peetz - CEO Peter Radovich...
